Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.

Vaccine - 30 Nov 2006

Maas Alexander, Meens Jochen, Baltes Nina, Hennig-Pauka Isabel, Gerlach Gerald-F

Abstract excerpt

Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia which leads to high economic losses in the swine industry worldwide. Vaccination against this pathogen is hampered by the occurrence of 15 serotypes, and commonly used whole cell bacterin vaccines are not sufficiently cross-serotype protective. In addition, for generating and maintaining specified pathogen-free herds it is desirable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Actinobacillus Infections
Share to Actinobacillus pleuropneumoniae

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibody Formation

Share to Bacterial Outer Membrane Proteins

Share to Bacterial Vaccines

Share to Swine Diseases

Share to Vaccination

Share to Vaccines, Subunit

Source

Identifiers

PMID: 17027123
DOI: 10.1016/j.vaccine.2006.06.047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.PMID 17027123Read ↗

New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.Semantic proximity Read ↗

Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.Semantic proximity Read ↗

Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals.Semantic proximity Read ↗

Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.Semantic proximity Read ↗

Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.Semantic proximity Read ↗

Sero- and apx-typing of German Actinobacillus pleuropneumoniae field isolates from 2010 to 2019 reveals a predominance of serovar 2 with regular apx-profile.Semantic proximity Read ↗

Characterization of apxlVA, a new RTX determinant of Actinobacillus pleuropneumoniaeSemantic proximity Read ↗

Comparison of molecular serotyping methods for Actinobacillus pleuropneumoniae and analysis of atypical serotypes detected in routine diagnosticsSemantic proximity Read ↗

A new variant of Actinobacillus pleuropneumoniae serotype 3 lacking the entire apxII operon.Semantic proximity Read ↗

Construction and immunogenicity of a ∆apxIC/ompP2 mutant of Actinobacillus pleuropneumoniae and Haemophilus parasuis.Semantic proximity Read ↗

Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine.Semantic proximity Read ↗

Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.